Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 190.00
-4.50 (-2.31%)
Aug 22, 2025, 1:30 PM CST
Caliway Biopharmaceuticals Company Description
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation.
The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment.
It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements.
The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
Caliway Biopharmaceuticals Co., Ltd.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Yufang Ling |
Contact Details
Address: No.99, Xintai 5th Road New Taipei City, 221 Taiwan | |
| Phone | 886 2 2697 1355 |
| Website | caliway.com.tw |
Stock Details
| Ticker Symbol | 6919 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006919004 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yufang Ling | Chief Executive Officer and Research & Development Chief |
| Lu-hui Hsu | Chief Strategy Officer and Chairman |